Neurocrine Biosciences Inc

Healthcare · Drug Manufacturers - Specialty & Generic

145.50$ +0.9% vs. previous close Closing price · As of: Oct 6, 2026

Statements

Income Statement

Neurocrine Biosciences Inc (NBIX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 959 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement NBIX
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	15	15	0.0	6.3	61	95	71	97	152	131	138	184	222	244	237	302	259	248	237	289	296	312	311	378	388	412	420	453	499	515	515	590	622	628	573	688	795	806	815	959	3,374
Cost of Revenue	38	46	49	0.1	0.4	0.8	1.0	0.9	1.6	1.5	1.1	1.6	2.2	2.5	2.1	2.4	2.7	2.9	2.9	3.1	4.2	4.1	4.6	4.8	6.1	7.7	8.5	12	11	8.5	7.5	9.2	8.0	9.3	9.2	11	14	18	14	23	69
Gross Profit	0.0	-21	0.0	6.3	60	94	70	96	150	130	137	182	220	242	235	300	256	245	234	286	292	308	306	373	382	404	412	441	488	507	508	581	614	618	563	676	781	788	801	936	3,305
Research & Development	21	23	52	22	22	26	49	37	35	39	38	62	45	55	58	81	69	67	73	75	93	87	102	136	108	118	140	146	142	138	159	191	195	186	263	244	250	258	296	327	1,131
Selling, General & Administrative	17	24	28	42	44	56	59	61	60	69	88	81	84	253	118	97	113	107	129	143	155	157	201	183	186	183	243	222	204	219	243	242	234	288	277	286	292	302	319	440	1,352
Total Operating Expenses	38	46	80	64	66	82	108	98	96	108	238	148	130	193	176	223	300	173	202	223	247	244	303	319	294	301	526	368	346	356	409	436	430	476	540	531	542	577	615	783	2,516
Operating Income	-38	-46	-80	-57	-6.0	12	-37	-1.9	54	22	-101	34	90	49	59	77	-44	72	32	63	45	64	3.1	55	88	103	-114	74	141	150	99	145	184	142	24	146	239	211	186	153	789
Interest Expense	0.0	20	0.0	4.8	7.3	7.4	7.5	7.6	7.7	7.8	7.9	7.9	8.0	8.1	8.2	8.3	8.5	7.8	6.4	6.2	6.6	6.6	2.6	2.2	1.2	1.1	1.1	1.3	1.1	1.1	1.1	50	–	–	–	0.0	–	–	–	2.9	–
Pre-Tax Income	-37	-45	-78	-60	-11	6.9	-42	-5.9	51	19	-103	52	58	39	39	83	-57	42	27	58	31	-14	21	-23	98	118	-103	122	116	198	35	99	190	163	15	160	292	239	247	162	940
Income Tax Expense	-1.5	-2.0	-1.6	4.8	7.3	6.7	7.5	7.6	7.7	0.7	-0.5	0.8	4.6	4.6	1.5	3.6	0.5	-306	-4.9	15	8.0	-6.5	7.5	-6.4	29	29	-27	26	33	51	-8.9	34	61	60	6.8	52	82	86	49	18	235
Net Income	-37	-45	-78	-60	-11	6.9	-42	-5.9	51	18	-102	51	54	34	37	80	-58	348	32	42	23	-7.3	14	-17	69	89	-77	96	83	148	43	65	130	103	7.9	108	210	154	198	144	706
EBITDA	-36	-46	-78	-55	-3.2	15	-34	2.6	60	28	-93	62	68	49	49	94	-46	52	36	66	40	-4.2	27	-17	103	123	-97	127	122	205	112	155	191	182	31	167	300	235	193	190	918

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings